Mpex Pharmaceuticals, Inc.

Horizon Orphan LLC

Rempex Pharmaceuticals, Inc.

Other

Raptor Pharmaceuticals Inc.

Keith A Bostian

Mark William Surber

David C Griffith

Michael N Dudley

Olga Lomovskaya

Olga Rodny

Tomasz W Glinka

David Mark Wallace

Dongxu Sun

Brian Walter Eastman

Chi Ching Mak

Gavin C Hirst

Robert Higuchi

Neil Berkley

Chun Chow

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

Aerosolized fluoroquinolones and uses thereof

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

Aerosol fluoroquinolone formulations for improved pharmacokinetics

Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.

Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof

Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.

Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof

Efflux pump inhibitors are co-administered with antimicrobial agents for the treatment of ophthalmic or otic infections. The agents may be co-administered directly to the site of infection (e.g., the eye or ear).

Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections

This invention provides for efflux pump inhibitors to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens, novel efflux pump inhibitors, combined dosage forms of efflux pump inhibitors with an antimicrobial, and novel medical methods.

Use and administration of bacterial efflux pump inhibitors

This invention relates to the field of antimicrobial agents and more specifically it relates to Efflux Pump Inhibitor (EPI) compounds to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. The invention includes novel compounds useful as efflux pump inhibitors, compositions and devices comprising such efflux pump inhibitors, and therapeutic use of such compounds.

Growing community of inventors

Atherton, CA, United States of America

Keith A Bostian